Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
04 January 2018 - 11:00PM
Business Wire
Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it
will present at the 36th Annual J.P. Morgan Healthcare Conference
in San Francisco, CA on Thursday, January 11 at 8:30 a.m. PT.
A live audio webcast of the presentation and breakout question
and answer session will be available under the “Investors and
Media” section of Seres’ website. A replay of the presentation will
become available approximately one hour after the event and will be
archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics
platform company developing a novel class of biological drugs that
are designed to treat disease by restoring the function of a
dysbiotic microbiome, where the natural state of bacterial
diversity and function is imbalanced. Seres’ lead program, SER-109,
has obtained Breakthrough Therapy and Orphan Drug designations from
the U.S. Food and Drug Administration and is in Phase 3 development
for multiply recurrent C. difficile infection. Seres’ clinical
candidate SER-287 has successfully completed a Phase 1b study in
patients with mild-to-moderate Ulcerative Colitis. Seres is also
developing SER-262, the first ever synthetic microbiome therapeutic
candidate, in a Phase 1b study in patients with primary C.
difficile infection. For more information, please visit
www.serestherapeutics.com. Follow us on Twitter @SeresTx.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180104005392/en/
IR or PR Contact:Seres
TherapeuticsCarlo Tanzi, Ph.D., 617-203-3467Head of Investor
Relations and Corporate
Communicationsctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2024 to May 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From May 2023 to May 2024